Treatment Of Inflammatory Bowel Disease In Subjects Having Loss-Of-Function (LOF) Gene Variants

A method of treating a subject having Inflammatory Bowel Disease (IBD) or at risk of developing IBD by administering an IBD therapeutic agent, the method comprising:

• determining or having determined whether the subject has an Indoleamine 2,3-Dioxygenase 2 (IDO2) variant nucleic acid molecule, by:
• obtaining or having obtained a biological sample from the subject;
• and
• performing or having performed a sequence analysis on the biological sample to determine if the subject has a genotype comprising an IDO2 variant nucleic acid molecule;
• and
• administering or continuing to administer the IBD therapeutic agent in an amount that is the same as a standard dosage amount to a subject that is IDO2 reference;
• or
• administering or continuing to administer the IBD therapeutic agent in an amount that is the same as or less than a standard dosage amount, and/or an IDO2 agonist to a subject that is heterozygous or homozygous for the IDO2 variant nucleic acid molecule;
• wherein the presence of the IDO2 variant nucleic acid molecule indicates the subject has an increased risk of developing IBD.

A method of identifying a subject having an increased risk of developing Inflammatory Bowel Disease (IBD), the method comprising:

• determining or having determined the presence or absence of an Indoleamine 2,3-Dioxygenase 2 (IDO2) variant nucleic acid molecule in a biological sample obtained from the subject;
• wherein:
• when the subject is IDO2 reference, then the subject has a decreased risk of developing IBD;
• and
• when the subject is heterozygous or homozygous for the IDO2 variant nucleic acid molecule, then the subject has an increased risk of developing IBD.

A method of treating a subject having Inflammatory Bowel Disease (IBD) or at risk of developing IBD by administering an IBD therapeutic agent, the method comprising:

• determining or having determined whether the subject has a SMAD Family Member 2 (SMAD2) variant nucleic acid molecule, by:
• obtaining or having obtained a biological sample from the subject;
• and
• performing or having performed a sequence analysis on the biological sample to determine if the subject has a genotype comprising a SMAD2 variant nucleic acid molecule;
• and
• administering or continuing to administer the IBD therapeutic agent in an amount that is the same as a standard dosage amount to a subject that is SMAD2 reference;
• or
• administering or continuing to administer the IBD therapeutic agent in an amount that is the same as or less than a standard dosage amount, and/or a SMAD2 agonist to a subject that is heterozygous or homozygous for the SMAD2 variant nucleic acid molecule;
• wherein the presence of the SMAD2 variant nucleic acid molecule indicates the subject has an increased risk of developing IBD.

A method of identifying a subject having an increased risk of developing Inflammatory Bowel Disease (IBD), the method comprising:

• determining or having determined the presence or absence of a SMAD Family Member 2 (SMAD2) variant nucleic acid molecule in a biological sample obtained from the subject;
• wherein:
• when the subject is SMAD2 reference, then the subject has a decreased risk of developing IBD;
• and
• when the subject is heterozygous or homozygous for the SMAD2 variant nucleic acid molecule, then the subject has an increased risk of developing IBD.